Table 1

Baseline patient characteristics

n = 456Patients, %Erythroid response (IWG 2006 criteria)Univariate analysis PMultivariate analysis P
Hb, g/dL      
 <8 52 11 33   
 8-10 292 64 66   
 =10 112 25 78 <.0001  
ANC      
 <0.8 42 9 55   
 ≥0.8 414 91 66 .16  
Platelet count*      
 <50 17 3 37   
 50-100 58 13 57   
 >100 381 84 67 .01  
Marrow blasts, %      
 ≤2 238 52 72   
 <2-<5 118 26 61   
 5-10 100 22 53 .0052  
IPSS-R karyotype      
 Very good 21 5 71   
 Good 379 83 65   
 Intermediate 45 10 75   
 Poor-very poor 11 2 20 .008  
IPSS      
 Low 256 55 72   
 Int-1 210 45 52 .001  
IPSS-R      
 Very low 69 15 85   
 Low 281 61 68   
 Intermediate 87 19 48   
 High 19 4 31 <.0001 <.0001 
Sex      
 Male 250 55 62   
 Female 206 45 68 .14  
Age, years      
 ≤60 29 6 55   
 >60 427 94 66 .23  
EPO, mU/mL      
 ≤100 306 67 75   
 >100 150 33 45 <.0002  
 ≤200 393 86 75   
 >200 63 13 31 <.0001 <.0001 
Serum ferritin, ng/mL      
 ≤350 224 49 72   
 >350 232 51 58 .001 .002 
Previous RBC transfusions      
 No 323 71 73   
 Yes 133 29 55 .0005  
WHO classification      
 RA 110 24 73   
 RAEB-1 69 15 50   
 RARS 114 25 70   
 RARS-T 2 0.3 100   
 RCMD 124 27 62   
 MDS WITH DEL 5q 21 5 62   
 MDS-U 16 4 55 .03 .71 
n = 456Patients, %Erythroid response (IWG 2006 criteria)Univariate analysis PMultivariate analysis P
Hb, g/dL      
 <8 52 11 33   
 8-10 292 64 66   
 =10 112 25 78 <.0001  
ANC      
 <0.8 42 9 55   
 ≥0.8 414 91 66 .16  
Platelet count*      
 <50 17 3 37   
 50-100 58 13 57   
 >100 381 84 67 .01  
Marrow blasts, %      
 ≤2 238 52 72   
 <2-<5 118 26 61   
 5-10 100 22 53 .0052  
IPSS-R karyotype      
 Very good 21 5 71   
 Good 379 83 65   
 Intermediate 45 10 75   
 Poor-very poor 11 2 20 .008  
IPSS      
 Low 256 55 72   
 Int-1 210 45 52 .001  
IPSS-R      
 Very low 69 15 85   
 Low 281 61 68   
 Intermediate 87 19 48   
 High 19 4 31 <.0001 <.0001 
Sex      
 Male 250 55 62   
 Female 206 45 68 .14  
Age, years      
 ≤60 29 6 55   
 >60 427 94 66 .23  
EPO, mU/mL      
 ≤100 306 67 75   
 >100 150 33 45 <.0002  
 ≤200 393 86 75   
 >200 63 13 31 <.0001 <.0001 
Serum ferritin, ng/mL      
 ≤350 224 49 72   
 >350 232 51 58 .001 .002 
Previous RBC transfusions      
 No 323 71 73   
 Yes 133 29 55 .0005  
WHO classification      
 RA 110 24 73   
 RAEB-1 69 15 50   
 RARS 114 25 70   
 RARS-T 2 0.3 100   
 RCMD 124 27 62   
 MDS WITH DEL 5q 21 5 62   
 MDS-U 16 4 55 .03 .71 

ANC, absolute neutrophil count; IWG, International Working Group; MDS-U, MDS-unclassified; MDS WITH DEL, MDS associated with isolated del (5q); RA, refractory anemia; RAEB-1, refractory anemia with excess blasts-1; RARS, refractory anemia with ring sideroblasts; RARS-T, refractory anemia with ring sideroblasts associated with marked thrombocytosis; RCMD, refractory cytopenia with multilineage dysplasia; WHO, World Health Organization.

Univariate and multivariate analyses for response (IWG 2006 criteria). The variables with significant prognostic value in univariate analysis were integrated in the multivariate analysis, excepting Hb, platelet count, IPSS-R karyotype, and % of blasts, because IPSS-R integrates already those variables. For EPO level, the 200 mUI/mL threshold was chosen because it was the most significant in univariate analysis. Previous transfusions were not integrated in the model because they “duplicate” the Hb variable.

*

109/L.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal